Treatment of Mucosal Leishmaniasis with a Lipid Formulation of Amphotericin B

Amato, Valdir Sabbaga; Tuon, Felipe Francisco; Campos, Aléia Faustina; Bacha, Hélio Arthur; Nicodemo, Antônio Carlos; Neto, Vicente Amato; Shikanai-Yasuda, Maria Aparecida

doi:10.1086/510494

Cited by 29 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunotherapy represents a promising therapeutic approach to treatment of active leishmaniasis since no significant drug has emerged over the past 40 years (8,9,11). Vaccine adjuvants and immunotherapy for leishmaniasis have yielded promising results (3,39,90).…”

Section: Use Of Tlrmentioning

confidence: 99%

Toll-Like Receptors and Leishmaniasis

et al. 2008

View full text Add to dashboard Cite

Section: Use Of Tlrmentioning

confidence: 99%

Toll-Like Receptors and Leishmaniasis

et al. 2008

View full text Add to dashboard Cite

“…3,13,14 The aim of this study was to evaluate the clinical response of liposomal amphotericin B use for the treatment of American ML. We evaluated patients from the Institute of Infectious Diseases Emílio Ribas presenting with ML and contraindication to treatment using pentavalent antimonials, according to the assessment of the medical assistance team.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study

Cunha¹,

Leão²,

Soler³

et al. 2015

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents.

show abstract

“…4 However, this is the first case of simultaneous mucosal and cutaneous leishmaniasis reactivation caused by The treatment of mucosal and cutaneous forms of NWL is well established, 7,8 however patients with renal transplantation must use drugs with lower nephrotoxicity to avoid the renal failure. 9 Considering the current arsenal of treatment, the drug used for this case was a lipid formulation of amphotericin B. 10 These reports call attention to physicians to manage these cases for the possibility of leishmaniasis reactivation in transplanted patients.…”

Section: Discussionmentioning

confidence: 99%

Reactivation of Mucosal and Cutaneous Leishmaniasis in a Renal Transplanted Patient

Tuon

Bombonatto

Battaglin

et al. 2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Mucosal leishmaniasis (ML) is a chronic form of tegumentary leishmaniasis, which causes destructive lesions of nasal, pharyngeal, and laryngeal mucosa. We describe a case of leishmaniasis reactivation with simultaneous cutaneous and mucosal forms in a renal transplanted patient with no history of prior leishmaniasis. Reactivation after renal transplantation was not reported in Brazil. A 67-year-old woman receiving prednisone 20 mg/day, tacrolimus 1 mg/day, and mycophenolic acid 360 mg/day presented with nose edema with erythema and cutaneous lesions. Amastigotes were identified on biopsies and the polymerase chain reaction confirmed Leishmania (Viannia) braziliensis. The patient was treated with liposomal amphotericin B but died 3 weeks after as a result of bacterial septic shock. In conclusion, tegumentary leishmaniasis can reactivate with simultaneous cutaneous and mucosal forms in a renal transplanted patient during the immunosuppressant therapy.

show abstract

Treatment of Mucosal Leishmaniasis with a Lipid Formulation of Amphotericin B

Cited by 29 publications

References 8 publications

Toll-Like Receptors and Leishmaniasis

Toll-Like Receptors and Leishmaniasis

Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study

Reactivation of Mucosal and Cutaneous Leishmaniasis in a Renal Transplanted Patient

Contact Info

Product

Resources

About